Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.49

0.38 (1.15%)

, MRK

Merck

$54.90

(0.00%)

06:32
02/15/18
02/15
06:32
02/15/18
06:32

AstraZeneca, Merck: FDA grants Orphan Drug Designation for selumetinib

AstraZeneca (AZN( and Merck (MRK) announced that the U.S. FDA has granted Orphan Drug Designation for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1. The potential benefit of selumetinib in NF1 is being explored in the U.S. National Cancer Institute-sponsored phase 1/2 SPRINT trial in pediatric patients with symptomatic NF1-related PNs. Phase II trial results are expected later in 2018.

AZN

AstraZeneca

$33.49

0.38 (1.15%)

MRK

Merck

$54.90

(0.00%)

  • 15

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Oct

AZN AstraZeneca
$33.49

0.38 (1.15%)

01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/02/18
ADAM
01/02/18
NO CHANGE
Target $77
ADAM
Buy
ANI Pharmaceuticals best positioned in emerging generics space, says Canaccord
Canaccord analyst Dewey Steadman said ANI Pharmaceuticals (ANIP) is one of the best positioned names in the emerging generics space. He noted the company has a basket of additional branded tail assets from its AstraZeneca (AZN) acquisitions, additional cash on hand and credit facilities for future transactions, and a solid core business. Steadman reiterated his Buy rating and raised his price target to $77 from $75 on ANI Pharmaceuticals shares.
12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Overweight
AstraZeneca upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded AstraZeneca to Overweight and raised his price target for the shares to 55 pounds from 48 pounds. The company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium, Gordon tells investors in a research note. He believes downside risk around the Mystic trial failure and "overly high base business expectations" have now lessened with consensus earnings forecasts declining 15%. The analyst expects AstraZeneca to return to sales growth in 2018, even without further immuno-oncology trial success. Astra has 10 Phase III readouts, with fairly low expectations across the board, Gordon argues.
MRK Merck
$54.90

(0.00%)

02/14/18
BMOC
02/14/18
NO CHANGE
Target $65
BMOC
Outperform
Merck price target lowered to $65 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Merck to $65 after the company discontinued its APECS study. The analyst sees this as "another setback that increases Merck's dependence on Keytruda" and contends that the company needs other meaningful drivers. Arfaei keeps his Outperform rating based on his confidence in Keytruda growth and Merck's Immuno-oncology execution.
01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.
01/16/18
01/16/18
UPGRADE
Target $72

Buy
Merck upgraded on earlier than expected Keytruda trial success at SunTrust
As previously reported, SunTrust analyst John Boris upgraded Merck to Buy from Hold, stating that he had expected positive data from the Keynote-189 trial but that the positive results on Progression Free Survival and Overall Survival came earlier than expected. This timing should enable Merck to maintain its first-mover advantage in first-line non-squamous Non-Small Cell Lung Cancer, or NSCLC, in the U.S. and file in the EU, Boris tells investors. He raised his price target to $72 from $54 on Merck shares, which are up $4.09, or 7%, to $62.75 in morning trading.
01/16/18
RHCO
01/16/18
UPGRADE
RHCO
Buy
Merck upgraded to Buy from Hold at SunTrust

TODAY'S FREE FLY STORIES

CIEN

Ciena

$34.90

2.765 (8.60%)

07:36
12/14/18
12/14
07:36
12/14/18
07:36
Recommendations
Ciena analyst commentary  »

Ciena price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.39

-0.14 (-0.57%)

, C

Citi

$55.77

-0.22 (-0.39%)

07:35
12/14/18
12/14
07:35
12/14/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BAC

Bank of America

$24.39

-0.14 (-0.57%)

C

Citi

$55.77

-0.22 (-0.39%)

JD

JD.com

$22.71

0.81 (3.70%)

WFC

Wells Fargo

$47.03

-0.72 (-1.51%)

M

Macy's

$30.80

-1.0425 (-3.27%)

SBUX

Starbucks

$66.90

0.8 (1.21%)

CLF

Cleveland-Cliffs

$8.23

-0.135 (-1.61%)

MET

MetLife

$39.52

-0.05 (-0.13%)

NWL

Newell Brands

$22.78

-0.785 (-3.33%)

MRVL

Marvell

$15.64

0.29 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 06

    Jan

  • 08

    Jan

  • 14

    Jan

  • 15

    Jan

  • 12

    Feb

  • 12

    Apr

  • 15

    Apr

  • 18

    Jun

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

ICLR

Icon

$136.31

-1.83 (-1.32%)

07:34
12/14/18
12/14
07:34
12/14/18
07:34
Downgrade
Icon rating change  »

Icon downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORTX

Orchard Therapeutics

$15.01

-0.29 (-1.90%)

07:33
12/14/18
12/14
07:33
12/14/18
07:33
Hot Stocks
Orchard Therapeutics, SIRION Biotech enter license agreement for LentiBOOST »

Orchard Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$16.33

-0.24 (-1.45%)

07:32
12/14/18
12/14
07:32
12/14/18
07:32
Downgrade
Amneal Pharmaceuticals rating change  »

Amneal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GE

General Electric

$7.20

0.48 (7.14%)

, OSTK

Overstock.com

$17.97

-1.13 (-5.92%)

07:30
12/14/18
12/14
07:30
12/14/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$7.20

0.48 (7.14%)

OSTK

Overstock.com

$17.97

-1.13 (-5.92%)

GME

GameStop

$12.79

-0.445 (-3.36%)

ESRX

Express Scripts

$98.94

2.03 (2.09%)

CC

Chemours

$27.15

0.485 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:30
12/14/18
12/14
07:30
12/14/18
07:30
General news
Treasury Market Outlook: yields are dropped on risk-off flows »

Treasury Market Outlook:…

SEE

Sealed Air

$32.41

-1.05 (-3.14%)

07:29
12/14/18
12/14
07:29
12/14/18
07:29
Upgrade
Sealed Air rating change  »

Sealed Air upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

07:27
12/14/18
12/14
07:27
12/14/18
07:27
Recommendations
Adobe analyst commentary  »

Adobe valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COST

Costco

$226.41

-1.41 (-0.62%)

07:25
12/14/18
12/14
07:25
12/14/18
07:25
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$137.58

-0.26 (-0.19%)

07:25
12/14/18
12/14
07:25
12/14/18
07:25
Conference/Events
Visa management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 29

    Jan

BECN

Beacon Roofing

$31.84

-0.22 (-0.69%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$62.26

0.06 (0.10%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Regency Centers rating change  »

Regency Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DRGDF

Detour Gold

$0.00

(0.00%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$186.53

2.99 (1.63%)

, YUM

Yum! Brands

$93.49

3.02 (3.34%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Recommendations
McDonald's, Yum! Brands analyst commentary  »

JPMorgan calls…

MCD

McDonald's

$186.53

2.99 (1.63%)

YUM

Yum! Brands

$93.49

3.02 (3.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNN

National Retail Properties

$50.86

0.94 (1.88%)

07:18
12/14/18
12/14
07:18
12/14/18
07:18
Downgrade
National Retail Properties rating change  »

National Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRGDF

Detour Gold

$0.00

(0.00%)

07:16
12/14/18
12/14
07:16
12/14/18
07:16
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$3.60

-0.155 (-4.13%)

07:15
12/14/18
12/14
07:15
12/14/18
07:15
Hot Stocks
Bellicum Pharmaceuticals reports data from BPX-601 at ESMO-IO »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THG

Hanover Insurance

$109.52

-0.68 (-0.62%)

07:14
12/14/18
12/14
07:14
12/14/18
07:14
Conference/Events
Hanover Insurance management to meet with Buckingham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

BHC

Bausch Health

$23.65

-0.47 (-1.95%)

07:12
12/14/18
12/14
07:12
12/14/18
07:12
Upgrade
Bausch Health rating change  »

Bausch Health upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 25

    Feb

IDRA

Idera Pharmaceuticals

$6.60

-0.06 (-0.90%)

07:10
12/14/18
12/14
07:10
12/14/18
07:10
Hot Stocks
Idera Pharmaceuticals presents data from Phase 2 expansion of ILUMMINATE-204 »

Idera Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

RBA

Ritchie Bros.

$32.39

-0.28 (-0.86%)

07:08
12/14/18
12/14
07:08
12/14/18
07:08
Hot Stocks
Ritchie Bros. sells C$639M+ of equipment in Edmonton auction »

Ritchie Bros. held its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Recommendations
Starbucks analyst commentary  »

Starbucks story regaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Hot Stocks
EU passenger car registrations down 8.0% in November »

In November, passenger…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$120.89

-1.04 (-0.85%)

F

Ford

$8.50

-0.135 (-1.56%)

HMC

Honda

$27.23

-0.03 (-0.11%)

GM

General Motors

$35.11

-0.58 (-1.63%)

FCAU

Fiat Chrysler

$15.67

-0.18 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CPRX

Catalyst Pharmaceuticals

$2.47

0.075 (3.14%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.